Evidence Review
Stress and Cognitive Function — Randomized Controlled Trial
Hidese et al. (2019, PMID 31623400) conducted a double-blind, placebo-controlled, crossover trial in 30 healthy adults who received either 200 mg/day L-theanine or placebo for four weeks, then crossed over after a washout period. The L-theanine phase produced significant improvements on the Pittsburgh Sleep Quality Index (particularly sleep latency and disturbance subscales), reduced scores on the State-Trait Anxiety Inventory, and improved verbal fluency and executive function on cognitive testing. Salivary cortisol was not significantly different between conditions in this study, though the trend favored L-theanine. The crossover design strengthens internal validity; limitations include the relatively modest sample size (n=30) and healthy volunteer population that may underrepresent those with clinical anxiety.
L-Theanine and Caffeine — Cognitive Performance RCT
Giesbrecht et al. (2010, PMID 21040626) randomized 44 young adults to receive 97 mg L-theanine plus 40 mg caffeine, each agent alone, or placebo in a crossover design. The combination produced significantly greater accuracy during task switching (P < 0.01) and higher self-reported alertness (P < 0.01) compared to placebo. Importantly, the combination also significantly reduced self-reported tiredness (P < 0.05) compared to caffeine alone. The doses used are roughly equivalent to one moderate cup of coffee paired with a small green tea — a pharmacologically modest but practically relevant combination. This study contributed to a large body of literature (reviewed in PMID 24946991) confirming that combined L-theanine/caffeine outperforms either agent alone on tests of attention and mental accuracy.
Meta-Analysis of Tea Constituents on Cognition
Camfield et al. (2014, PMID 24946991) systematically reviewed 11 randomized placebo-controlled studies examining the acute cognitive effects of L-theanine, caffeine, and epigallocatechin gallate (EGCG) individually and in combination. The meta-analysis found that L-theanine alone produced significant improvements in attention and reaction time, with the most consistent effects seen when it was combined with caffeine. The authors noted heterogeneity across studies in terms of dosing (50–250 mg L-theanine) and outcome measures, making precise effect size estimates difficult. Overall conclusion: L-theanine has a reliable acute pro-cognitive effect, most pronounced in combination with caffeine and in individuals under stress or cognitive load.
Sleep Quality in ADHD — Placebo-Controlled Clinical Trial
Lyon, Kapoor & Juneja (2011, PMID 22214254) randomized 98 boys aged 8–12 with ADHD to receive 400 mg/day L-theanine (as two 100 mg chewable tablets twice daily) or identical placebo for 6 weeks. Objective sleep data were collected via actigraphy over 5 nights. The L-theanine group showed significantly higher sleep efficiency scores (P < 0.05) and sleep percentage compared to placebo, along with reduced nocturnal activity. The study is notable for using objective rather than self-reported sleep measures. Limitations include a pediatric male-only sample that limits generalizability. However, the finding is significant because ADHD is associated with severe sleep disruption, and L-theanine provided measurable benefit without sedative side effects — suggesting its mechanism (reducing hyperarousal rather than inducing sedation) is genuine.
Psychotropic Effects — Clinical Narrative Review
Lopes Sakamoto et al. (2019, PMID 31412272) reviewed the clinical evidence for L-theanine's psychotropic properties across anxiety disorders, schizophrenia, ADHD, and healthy stress populations. Their synthesis of controlled trials found that 200–400 mg/day dosing for up to 8 weeks was consistently safe and produced anxiolytic effects across diverse populations. The review highlights the mechanism of alpha wave induction as central to L-theanine's calming properties and discusses the compound's potential as an adjuvant in psychiatric treatment — particularly for reducing the anxiety and cognitive impairments associated with schizophrenia without worsening positive symptoms. The authors conclude that L-theanine represents a genuinely promising natural anxiolytic but that larger Phase III trials are needed.
Depression and Mood — Open-Label Clinical Study
Hidese et al. (2017, PMID 27396868) administered 250 mg/day L-theanine for 8 weeks to 20 patients with major depressive disorder as an add-on to their current medications. Significant improvements were observed in depressive symptoms (Hamilton Depression Rating Scale), anxiety (STAI), sleep quality (PSQI), and cognitive measures including verbal memory and executive function. The lack of a placebo control is a significant limitation and precludes causal attribution. However, the consistent improvement across multiple domains — including objective cognitive tests — is suggestive that L-theanine has genuine neuropsychiatric activity beyond placebo. This study adds to the case for investigating L-theanine as an adjunct in depression management.
Overall Evidence Assessment
The evidence base for L-theanine is broader and more consistent than most natural supplements. Multiple well-designed RCTs support acute and short-term benefits for anxiety, stress, and cognitive performance — particularly in combination with caffeine. Sleep quality improvements have been demonstrated with both objective and subjective measures. The evidence for depression and ADHD is promising but requires larger controlled trials. Across all studies, the safety profile is excellent: no serious adverse events, no tolerance development, and no dependency. The primary caveat is that most trials are short (4–8 weeks) and use moderate doses (200–400 mg), leaving long-term effects and optimal dosing less certain.